SuperworthRevvity revenue RVTY
Sales by quarter and over the last twelve months, from 2009.
- Last 12 months, to Jul 5, 2026
- $2.9B
- Latest quarter, Q2 FY26
- $729.7M
- +1% on a year earlier
- Fiscal year 2025
- $2.9B
- +4% on the year before
Revvity's revenue was $2.9B over the twelve months to Jul 5, 2026, up 4% on a year earlier.
In its latest quarter, Q2 FY26, it was $729.7M, up 1% on the same quarter a year before.
Over the five fiscal years to FY2025 it shrank 5% a year on average.
Revenue over time
Fiscal year by fiscal year
| Fiscal year | Revenue | Change |
|---|---|---|
| FY2025 | $2.9B | +4% |
| FY2024 | $2.8B | +0% |
| FY2023 | $2.8B | −17% |
| FY2022 | $3.3B | −30% |
| FY2021 | $4.8B | +26% |
| FY2020 | $3.8B | +31% |
| FY2019 | $2.9B | +4% |
| FY2018 | $2.8B | +23% |
| FY2017 | $2.3B | +7% |
| FY2016 | $2.1B | −6% |
| FY2015 | $2.3B | +1% |
| FY2014 | $2.2B | +4% |
| FY2013 | $2.2B | +2% |
| FY2012 | $2.1B | +10% |
| FY2011 | $1.9B | +13% |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | Revenue | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $729.7M | +1% | $2.9B | |
| Q1 FY26 | $711.1M | +7% | $2.9B | |
| Q4 FY25 | $772.1M | +6% | $2.9B | |
| Q3 FY25 | $698.9M | +2% | $2.8B | |
| Q2 FY25 | $720.3M | +4% | $2.8B | |
| Q1 FY25 | $664.8M | +2% | $2.8B | |
| Q4 FY24 | $729.4M | +5% | $2.8B | |
| Q3 FY24 | $684M | +2% | $2.7B | |
| Q2 FY24 | $691.7M | −2% | $2.7B | |
| Q1 FY24 | $649.9M | −4% | $2.7B | |
| Q4 FY23 | $695.9M | −6% | $2.8B | |
| Q3 FY23 | $670.7M | −6% | $2.8B |
Against its peers
Companies in Medical - Diagnostics & Research nearest Revvity's size, closest first, today.
| Company | Revenue, 12 months | Growth |
|---|---|---|
| RVTYRevvity | $2.9B | +4% a year |
| MEDPMedpace | $2.8B | +25% a year |
| LHLabcorp | $14.3B | +6% a year |
| DGXQuest Diagnostics | $11.6B | +9% a year |
| BIOBio-Rad Laboratories | $2.6B | +1% a year |
| MTDMettler-Toledo International | $4.1B | +7% a year |
| CAICaris Life Sciences | $989.6M | +85% a year |
| ILMNIllumina | $4.5B | +5% a year |
| IDXXIDEXX Laboratories | $4.6B | +13% a year |
| WATWaters | $4.6B | +52% a year |
| IQVIQVIA | $17B | +8% a year |
| Peer median | $4.5B |
Where Revvity ranks
What the revenue tells you
Total sales in the period. On the company page, quarterly bars or the trailing twelve months (TTM), which smooths seasonality.
Growing revenue with shrinking margins is a warning, not a win.
More on Revvity
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.